Nástroje

iconicon Akciový screener
iconicon Kalendář zisků
iconicon Super investoři

Ostatní

iconicon Návod
IČ: 19940963

5. května 521, 501 01 Turnov
Zásady GDPR
Podmínky služby
Všechna práva vyhrazena @ 2024, Fundamenty.cz
Proudly created by draftspot.net
Generation Bio Co.
Generation Bio Co.
GBIO
Valuace
70
Růst
30
Zdraví
75
Cena
$ 5.34
Dnes
-0.02 (-0.35%)
Souhrn
Výkazy
Ukazatele
Profil
Držitelé
Návštěvnost webu
Konkurence
Zprávy společnosti
Kapitalizace
0.0B
Obrat
0B
Zisk
0B
Aktiva
0B
Dluh
0B
ROE
-124%
ROA
-51%
PE
-1
PS
2
Cena 1R
3-10
⌀ Cena
4.95
Dividenda
0.0(0.0%)
Čtvrtletní 10-Q
10-Q
Celoroční 10-K
8-K
Nadcházející oznámení zisků
Poslední dividenda

Profil

Generation Bio Co., společnost zabývající se genetickými léčivými přípravky, vyvíjí terapie pro léčbu vzácných a rozšířených onemocnění. Společnost poskytuje portfolio programů, včetně programů pro vzácné a rozšířené onemocnění jater a retiny. Zaměřuje se také na onemocnění kosterního svalstva, centrálního nervového systému a onkologii. Společnost byla dříve známá jako Torus Therapeutics, Inc. a v listopadu 2017 změnila svůj název na Generation Bio Co. Společnost Generation Bio Co. byla založena v roce 2016 a sídlí v Cambridge ve státě Massachusetts.
Sektor
Healthcare
Odvětví
Biotechnology
Počet zaměstnanců
115
Založení
2020-06-12
Adresa
301 Binney Street
CEO
Cameron Geoffrey McDonough
Web
generationbio.com

Podobné společnosti

VRCA
Verrica Pharmaceuticals Inc.
$ 3.66
+ $ 0.18
JSPR
Jasper Therapeutics, Inc.
$ 1.89
+ $ 0.11

Zahraniční články

Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide

Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide

19:30 15-03-2026

INCHEON, Korea--(BUSINESS WIRE)-- #Biosimilar--Samsung Bioepis Co., Ltd. and Epis NexLab Co., Ltd., ...

Brokerages Set Generation Bio Co. (NASDAQ:GBIO) PT at $9.25

Brokerages Set Generation Bio Co. (NASDAQ:GBIO) PT at $9.25

1:44 19-12-2025

Generation Bio Co. (NASDAQ: GBIO - Get Free Report) has been assigned an average rating of "Hold" fr...

Shareholder Alert: The Ademi Firm investigates whether Generation Bio Co. is obtaining a Fair Price for its Public Shareholders

Shareholder Alert: The Ademi Firm investigates whether Generation Bio Co. is obtaining a Fair Price for its Public Shareholders

20:21 15-12-2025

MILWAUKEE , Dec. 15, 2025 /PRNewswire/ -- The Ademi Firm is investigating Generation Bio (Nasdaq: G...

GBIO Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Generation Bio Co. is Fair to Shareholders

GBIO Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Generation Bio Co. is Fair to Shareholders

19:38 15-12-2025

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t...

Generation Bio Announces Third Quarter 2025 Financial Results

Generation Bio Announces Third Quarter 2025 Financial Results

16:05 05-11-2025

CAMBRIDGE, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnolo...

Comparing Generation Bio (NASDAQ:GBIO) & Nuvation Bio (NYSE:NUVB)

Comparing Generation Bio (NASDAQ:GBIO) & Nuvation Bio (NYSE:NUVB)

3:58 30-10-2025

Generation Bio (NASDAQ: GBIO - Get Free Report) and Nuvation Bio (NYSE: NUVB - Get Free Report) are ...

Generation Bio Announces CEO Transition

Generation Bio Announces CEO Transition

16:05 22-10-2025

• Geoff McDonough, MD to step down as CEO & President and become Chair of the Company's Board of D...

Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates

Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates

18:31 12-08-2025

Generation Bio Co. (GBIO) came out with a quarterly loss of $3.12 per share versus the Zacks Consens...

Generation Bio Announces New Data for Its Novel ctLNP Delivery System and Early T Cell Programs and Reports Second Quarter 2025 Financial Results

Generation Bio Announces New Data for Its Novel ctLNP Delivery System and Early T Cell Programs and Reports Second Quarter 2025 Financial Results

16:05 12-08-2025

• New data confirm highly selective profile of cell-targeted lipid nanoparticle (ctLNP) and first-...

Generation Bio Announces 1-for-10 Reverse Stock Split

Generation Bio Announces 1-for-10 Reverse Stock Split

8:35 18-07-2025

CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnolo...

Squarepoint Ops LLC Takes Position in Generation Bio Co. (NASDAQ:GBIO)

Squarepoint Ops LLC Takes Position in Generation Bio Co. (NASDAQ:GBIO)

3:34 11-06-2025

Squarepoint Ops LLC purchased a new position in Generation Bio Co. (NASDAQ:GBIO – Free Report)...

Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates

Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates

18:41 07-05-2025

Generation Bio Co. (GBIO) came out with a quarterly loss of $0.22 per share versus the Zacks Consens...

Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results

Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results

16:05 07-05-2025

-  Company continues to advance its strategy to develop first-in-class treatments for T cell-driven...

Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference

Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference

6:59 02-04-2025

CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnolo...

Generation Bio Co. (GBIO) Reports Q4 Loss, Tops Revenue Estimates

Generation Bio Co. (GBIO) Reports Q4 Loss, Tops Revenue Estimates

18:15 13-03-2025

Generation Bio Co. (GBIO) came out with a quarterly loss of $0.32 per share versus the Zacks Consens...

Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

16:05 13-03-2025

-  Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T ...

Tubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc.

Tubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc.

5:00 06-02-2025

MUNICH, Germany--(BUSINESS WIRE)--Tubulis today announced the appointment of Matthew Norkunas, MD, M...

Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases

Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases

16:30 06-01-2025

CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology...

Generation Bio Co. (GBIO) Reports Q3 Loss, Tops Revenue Estimates

Generation Bio Co. (GBIO) Reports Q3 Loss, Tops Revenue Estimates

18:45 06-11-2024

Generation Bio Co. (GBIO) came out with a quarterly loss of $0.23 per share versus the Zacks Consens...

Generation Bio Announces the Presentation of Preclinical Data on ctLNP and iqDNA at the ESGCT 31st Annual Congress

Generation Bio Announces the Presentation of Preclinical Data on ctLNP and iqDNA at the ESGCT 31st Annual Congress

6:59 22-10-2024

CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology...

Výsledovka

Rozvaha

Peněžní toky

Akciový screener
Kalendář zisků
Super investoři
Porovnání akcií
preloader